Cardiologia

O ano de 2021 na medicina cardiovascular: arritmias.

11 Fev, 2022 | 14:13h

The year in cardiovascular medicine 2021: arrhythmias – European Heart Journal

Conteúdos relacionados:

The year in cardiovascular medicine 2021: valvular heart disease.

The year in cardiovascular medicine 2021: diabetes and metabolic disorders.

The year in cardiovascular medicine 2021: heart failure and cardiomyopathies.

The year in cardiovascular medicine 2021: dyslipidemia.

Year in cardiovascular medicine: cardio-oncology 2020–21.

The year in cardiovascular medicine 2021: digital health and innovation.

---

Avaliação e tratamento da hipotensão ortostática: dados limitados, oportunidades ilimitadas.

11 Fev, 2022 | 13:48h

Evaluation and management of orthostatic hypotension: Limited data, limitless opportunity – Cleveland Clinic Journal of Medicine

---

Editorial | Substituição valvar aórtica transcateter: quando se deve dizer não?

11 Fev, 2022 | 13:46h

Predictors and clinical outcomes of poor symptomatic improvement after transcatheter aortic valve replacement – openheart

Editorial: Transcatheter aortic valve replacement: when should we say no? – openheart

---

Revisão | Avanços no tratamento do AVC cardioembólico associado com forame oval patente.

10 Fev, 2022 | 14:01h

Advances in the management of cardioembolic stroke associated with patent foramen ovale – The BMJ

Conteúdos relacionados:

Patent Foramen Ovale (PFO) After Stroke: Meta-analysis suggests the application of a multivariable causal classification system may better distinguish patient subgroups who may benefit from PFO closure from those unlikely to receive benefit.

Management of the Patient With Patent Foramen Ovale in 2021: A Spectrum of Cases

Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology – Neurology

---

M-A | Em pacientes com síndrome coronariana aguda submetidos a intervenção coronariana percutânea, a dupla terapia antiplaquetária (DAP) de curta duração foi comparável com a de-escalação da potência em relação a morte por todas as causas. A de-escalação reduziu o risco de eventos adversos cardiovasculares, enquanto a DAP reduziu sangramentos maiores.

10 Fev, 2022 | 13:43h

Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes – JACC: Cardiovascular Interventions (link para o resumo – $ para o texto completo)

Comentário: Short Duration of DAPT vs. De-Escalation After PCI for ACS – American College of Cardiology

---

Tratamento medicamentoso da insuficiência cardíaca com fração de ejeção reduzida: dicas clínicas baseadas em evidências para melhorar a terapia.

10 Fev, 2022 | 13:38h

Medication management for heart failure with reduced ejection fraction – Canadian Family Physician

---

[Preprint] Vigilância ativa de miocardite e pericardite decorrentes da vacinação contra COVID-19 com vacinas do tipo mRNA em pessoas de 12-39 anos na Itália.

10 Fev, 2022 | 13:13h

Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study -medRxiv

Conteúdos relacionados:

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Comentário no Twitter

The incidence of mRNA vaccine myocarditis or pericarditis in Italy in ~3 million vaccinees age 12-39. Excess cases per 100,000; orange is 2nd dose, blue 1st dose. https://t.co/xvdV4qSdHw
Pfizer:~1/100,000 age 12-39, all 2nd dose
Moderna,: >5/100,000, age 12-39, and some 1st dose pic.twitter.com/Y1jfGrU53v

— Eric Topol (@EricTopol) February 9, 2022

 

---

Apesar de raro, o risco de inflamação cardíaca foi maior em quem recebeu vacina contra Covid da Moderna do que naqueles que receberam a dose da Pfizer.

10 Fev, 2022 | 13:11h

Though rare, Moderna Covid vaccine recipients have higher risk of heart inflammation than Pfizer – CNBC

Conteúdos relacionados:

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

---

Estudo sugere que o rastreamento cardíaco de rotina não é necessário antes do retorno às atividades em atletas juvenis com infecção leve ou assintomática pelo SARS-CoV-2.

10 Fev, 2022 | 13:07h

SARS-CoV-2 infection and return to play in junior competitive athletes: is systematic cardiac screening needed? – British Journal of Sports Medicine

---

Revisão | Arritmia supraventricular na gestação.

10 Fev, 2022 | 12:58h

Supraventricular arrhythmia in pregnancy – Heart

---